Sarepta is way UNDERVALUED
$Sarepta Therapeutics (SRPT.US)$ SO THIS IS WHY ? Last quarter they raised the 2021 guidance to 605-615M and the slide in the presentation shows 612M unaudited annual revenue. $2.1B in cash. There is absolutely no reason the stock to sell off 12%, it is exactly what they guided , this is absolutely the best buying opportunity in the biotech sector period. Sarepta should be trading at $15B not pathetic 6.5B !
2021 Guidance Raised
Sarepta raised its guidance for revenues in 2021, following the strong performance of its three DMD drugs in the first nine months of 2021. The company now expects product revenues to be in the range of $605-$615 million, indicating year-over-year growth of nearly 34% at the midpoint of the range. Previously, the company expected the same to be between $565 million and $575 million.
2021 Guidance Raised
Sarepta raised its guidance for revenues in 2021, following the strong performance of its three DMD drugs in the first nine months of 2021. The company now expects product revenues to be in the range of $605-$615 million, indicating year-over-year growth of nearly 34% at the midpoint of the range. Previously, the company expected the same to be between $565 million and $575 million.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
